Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL), GELLC-7 trial from the Spanish group of CLL (GELLC)

  • Abrisqueta, Pau|||0000-0001-9625-7422
  • González Barca, Eva|||0000-0002-1323-1508
  • Ferrá, Christelle|||0000-0003-4571-5125
  • Ríos-Herranz, Eduardo
  • Fernández de la Mata, Margarita
  • Delgado, Julio|||0000-0002-5157-4376
  • Andreu, Rafael|||0000-0002-9220-3352
  • Hernández-Rivas, José Ángel
  • Terol, María José
  • Navarro, Almudena
  • Vidriales, M. Belén
  • Baltasar, Patricia
  • De La Serna, Javier|||0000-0003-3904-1101
  • Ramírez, Á.ngel
  • Ballester, C.
  • Moreno, Carol|||0000-0003-3275-0271
  • García-Marco, J.A.|||0000-0002-8993-5982
  • Córdoba, Raúl|||0000-0002-7654-8836
  • Yáñez, Lucrecia|||0000-0001-9925-3048
  • Casado, Luis Felipe
  • González, Marcos
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
BTK inhibitors have been concurrently administered with anti-CD20 monoclonal antibodies (mAbs) in chronic lymphocytic leukemia (CLL). However, the optimal regimen for combining these two drugs remains pending. Methods: This multi-center phase 2 study aimed to analyze whether consolidation with ofatumumab improved the response in patients with CLL receiving front-line treatment with ibrutinib. Patients received 12 cycles of ibrutinib monotherapy. Those who achieved CR after this induction were maintained on ibrutinib. Conversely, those who did not attain CR continued with ibrutinib in addition to a consolidation, which involved 7 doses of ofatumumab. The primary objective was the complete response (CR) rate at cycle 20. This study is registered within the EU Clinical Trials Register (EudraCT 2016-004937-26). Findings: Between September 8, 2017, and May 21, 2018, 84 patients (median age, 69 years) were included. After completion of 12 cycles of ibrutinib (n = 80), 4 patients (5%) were in CR, 67 (84%) in partial response (PR), and 6 patients (7%) had a PR with lymphocytosis (PRL). After consolidation with ofatumumab, 20 patients improved the response from PR to CR and 6 patients with PRL obtained a PR. Seventy-one patients (85%) completed 20 cycles of treatment, with a CR rate of 24/71 (34%). According to the intention-to-treat analysis at cycle 20, the ORR was 69/84 (82.2%), with a CRR of 24/84 (28.6%). Progression-free survival and overall survival at 48-months were 89.9% (CI: 82.4-95.5) and 92.2% (CI: 85.3-97.1), respectively. Interpretation: These findings underscore the potential for a consolidation strategy in CLL, wherein the addition of a mAb in patients with low tumor burden might enhance the quality of the response. Funding: The study was funded by Janssen that also supplied ibrutinib, whereas ofatumumab was supplied by Novartis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemia

  • Medina-Gil, Daniel|||0000-0001-9421-949X
  • Palomo Sanchís, Laura|||0000-0003-3176-6271
  • Navarro Garcés, Víctor|||0000-0001-6925-4605
  • Lázaro, Gonzalo|||0000-0002-7548-114X
  • Martín-Mur, Beatriz|||0000-0002-6006-3295
  • Hernández Buñuel, Cristina
  • Castells, Oriol
  • Sánchez, Belén
  • Muñoz-Torres, Pau Marc|||0000-0002-0168-3224
  • Pagès Geli, Carlota|||0000-0001-9200-3943
  • Pujadas, Gemma|||0000-0002-3871-5883
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Cabirta, Alba|||0000-0001-7198-8894
  • Ferrá, Christelle|||0000-0003-4571-5125
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • Terol, Maria Jose|||0000-0002-9467-932X
  • Andreu, Rafael|||0000-0002-9220-3352
  • Martí, Mercè|||0000-0002-1846-0043
  • Abrisqueta, Pau|||0000-0001-9625-7422
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
  • Crespo, Marta|||0000-0002-7732-7808
Continuous treatment with ibrutinib not only exerts tumor control but also enhances T-cell function in patients with chronic lymphocytic leukemia (CLL). We conducted longitudinal multi-omics analyses in samples from CLL patients receiving ibrutinib upfront to identify potential adaptive mechanisms to Bruton tyrosine kinase (BTK) inhibition during the first 12 months of continuous therapy. We found that ibrutinib induced a decrease in the expression of exhaustion markers and the proportion of regulatory T cells and T-follicular helper cells normalized to levels observed in healthy donors. Functionally, the expression of genes related to activation, proliferation, differentiation, and metabolism were downregulated in T cells; after in vitro stimulation, proliferation capacity was only slightly modified by ibrutinib treatment, while cytokine production was increased. In CLL cells, we observed a downregulation of immunosuppression, adhesion, and migration proteins. Adaptation at molecular level, characterized by an increase in cancer cell fraction of CLL cells with mutated driver genes, was observed in around half of the patients and was associated with retained migrative capacity towards CXCL12/CXCR4 axis. Interestingly, BTK C481S mutations were detected as early as after 6 months of treatment, particularly enriched in subsets of malignant cells retaining migrative capacity. These CLL cells with potential migrative capacity under ibrutinib also exhibited a distinct transcriptomic profile including upregulation of mTOR-AKT and MYC pathways. We identified the high expression of TMBIM6 as a potential novel independent poor prognostic factor. Of note, BIA, a TMBIM6 antagonist, induced CLL cell apoptosis and synergized with ibrutinib. In summary, our comprehensive multi-omics analysis of CLL patients undergoing ibrutinib therapy has unveiled early immunomodulatory effects on T cells and adaptative mechanisms in CLL cells. These findings can contribute to the identification of resistance mechanisms and the discovery of novel therapeutic targets.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders

  • Serna, Angel
  • Iraola, Josu
  • Garcia-Herce, Cristina
  • Falcó Roget, Anna
  • Navarro Garces, Victor
  • Jiménez, Moraima
  • Bosch Schips, Marc
  • Albasanz Puig, Adaia
  • Ruiz Camps, Isabel
  • Esperalba, Juliana
  • Cecilia del Carmen, Carpio Segura
  • Crespo, Marta
  • IACOBONI, GLORIA
  • Marin Niebla, Ana
  • Abrisqueta, Pau
  • Antón Pagarolas, Andrés
  • Andrés Vergés, Cristina
  • Bosch, Francesc
SARS-CoV-2 infection; Bispecific antibody; B-cell lymphoproliferative disorders, Infecció per SARS-CoV-2; Anticossos biespecífics; Trastorns limfoproliferatius de cèl·lules B, Infección por SARS-CoV-2; Anticuerpos biespecíficos; Trastornos linfoproliferativos de células B, Despite advances in vaccination and the use of antiviral treatments, patients with hematologic malignancies, including B-cell lymphoproliferative disorders, are particularly vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The recent introduction of bispecific antibodies (BsAbs) in the treatment algorithm of relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) has raised concerns regarding their impact on COVID-19 outcomes. This study aimed to evaluate the impact of SARS-CoV-2 infection on treatment outcomes in patients receiving BsAbs. We assessed the severity of COVID-19 and SARS-CoV-2 serostatus, with antibody titers measured before, during, and after BsAbs administration. A total of 109 patients with B-NHL treated with BsAbs from March 2020 to January 2023 were included. SARS-CoV-2 infection was observed in 56 patients (51%), with 36% experiencing prolonged viral shedding, causing therapy delays in 78% of patients and permanent discontinuations in 19%. Regarding COVID-19 severity, 36% of patients presented moderate, 20% severe, and 12% critical disease. Seven patients (13%) died owing to COVID-19 pneumonia. Similar to observations with anti-CD20 monoclonal antibodies, BsAbs were associated with negative antispike serostatus for at least 6 months after treatment completion. Importantly, this lack of seroconversion was linked with severe disease and increased mortality. These findings underscore important considerations for the management of patients receiving BsAbs., This work was supported by the Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias (PI22/01204).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemia

  • Medina-Gil, Daniel
  • Palomo Diaz, Laura
  • Lázaro, Gonzalo
  • Martín Mur, Beatriz
  • Hernández Pascual, Cristina
  • Castells, Oriol
  • Sánchez, Belén
  • Pagès Geli, Carlota
  • Pujadas, Gemma
  • Crespo, Marta
  • Navarro Garces, Victor
  • Muñoz-Torres, Pau Marc
  • Cabirta, Alba
  • Abrisqueta, Pau
  • Bosch, Francesc
Bruton tyrosine kinase covalent inhibition; Immune microenvironment; Chronic lymphocytic leukemia, Inhibición covalente de la tirosina quinasa de Bruton; Microambiente inmunitario; Leucemia linfocítica crónica, Inhibició covalent de la tirosina quinasa de Bruton; Microambient immunitari; Leucèmia limfocítica crònica, Continuous treatment with ibrutinib not only exerts tumor control but also enhances T-cell function in patients with chronic lymphocytic leukemia (CLL). We conducted longitudinal multi-omics analyses in samples from CLL patients receiving ibrutinib upfront to identify potential adaptive mechanisms to Bruton tyrosine kinase (BTK) inhibition during the first 12 months of continuous therapy. We found that ibrutinib induced a decrease in the expression of exhaustion markers and the proportion of regulatory T cells and T-follicular helper cells normalized to levels observed in healthy donors. Functionally, the expression of genes related to activation, proliferation, differentiation, and metabolism were downregulated in T cells; after in vitro stimulation, proliferation capacity was only slightly modified by ibrutinib treatment, while cytokine production was increased. In CLL cells, we observed a downregulation of immunosuppression, adhesion, and migration proteins. Adaptation at molecular level, characterized by an increase in cancer cell fraction of CLL cells with mutated driver genes, was observed in around half of the patients and was associated with retained migrative capacity towards CXCL12/CXCR4 axis. Interestingly, BTK C481S mutations were detected as early as after 6 months of treatment, particularly enriched in subsets of malignant cells retaining migrative capacity. These CLL cells with potential migrative capacity under ibrutinib also exhibited a distinct transcriptomic profile including upregulation of mTOR-AKT and MYC pathways. We identified the high expression of TMBIM6 as a potential novel independent poor prognostic factor. Of note, BIA, a TMBIM6 antagonist, induced CLL cell apoptosis and synergized with ibrutinib. In summary, our comprehensive multi-omics analysis of CLL patients undergoing ibrutinib therapy has unveiled early immunomodulatory effects on T cells and adaptative mechanisms in CLL cells. These findings can contribute to the identification of resistance mechanisms and the discovery of novel therapeutic targets., This work was supported by research funding from the Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias (PI21/01190, to MC) (PI20/01274 and PI24/00529 to FB), (PI22/01204 PA and Fundació la Marató de TV3 [201905-30-31] to FB). All Spanish funding was co-sponsored by the European Union FEDER program “Una manera de hacer Europa”. DM-G holds a contract from Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) (2022FI_B 00092).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

New Insights into First-Line Therapy in Diffuse Large B-Cell Lymphoma: Are We Improving Outcomes?

  • Abrisqueta, Pau
Diffuse large B-cell lymphoma; First-line therapy; Novel therapies, Limfoma difús de cèl·lules B grans; Teràpia de primera línia; Teràpies noves, Linfoma difuso de células B grandes; Terapia de primera línea; Terapias novedosas, Diffuse large B-cell lymphoma (DLBCL) is the most prevalent subtype of lymphoma, comprising heterogeneous patient subgroups with distinctive biological and clinical characteristics. The R-CHOP combination (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) has been the standard initial treatment, yielding prolonged remissions in over 60% of patients with advanced-stage disease. Several attempts to enhance the outcomes of this regimen over the last two decades have shown limited success. Various novel therapeutic approaches have recently emerged in lymphoma, demonstrating promising results. These include small molecules, novel monoclonal antibodies, antibody–drug conjugates (ADC), bispecific antibodies (BsAbs), and chimeric antigen receptor (CAR) T-cell therapy. This review explores recent advancements in therapeutic strategies for DLBCL and their potential impact on the initial management of DLBCL patients., This work was supported in part by the Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias [PI17/00943, PI22/01204].
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

New Insights into First-Line Therapy in Diffuse Large B-Cell Lymphoma, Are We Improving Outcomes?

  • Abrisqueta, Pau|||0000-0001-9625-7422
Diffuse large B-cell lymphoma (DLBCL) is the most prevalent subtype of lymphoma, comprising heterogeneous patient subgroups with distinctive biological and clinical characteristics. The R-CHOP combination (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) has been the standard initial treatment, yielding prolonged remissions in over 60% of patients with advanced-stage disease. Several attempts to enhance the outcomes of this regimen over the last two decades have shown limited success. Various novel therapeutic approaches have recently emerged in lymphoma, demonstrating promising results. These include small molecules, novel monoclonal antibodies, antibody-drug conjugates (ADC), bispecific antibodies (BsAbs), and chimeric antigen receptor (CAR) T-cell therapy. This review explores recent advancements in therapeutic strategies for DLBCL and their potential impact on the initial management of DLBCL patients.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

New Insights into First-Line Therapy in Diffuse Large B-Cell Lymphoma: Are We Improving Outcomes?

  • Abrisqueta, Pau
Diffuse large B-cell lymphoma; First-line therapy; Novel therapies, Limfoma difús de cèl·lules B grans; Teràpia de primera línia; Teràpies noves, Linfoma difuso de células B grandes; Terapia de primera línea; Terapias novedosas, Diffuse large B-cell lymphoma (DLBCL) is the most prevalent subtype of lymphoma, comprising heterogeneous patient subgroups with distinctive biological and clinical characteristics. The R-CHOP combination (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) has been the standard initial treatment, yielding prolonged remissions in over 60% of patients with advanced-stage disease. Several attempts to enhance the outcomes of this regimen over the last two decades have shown limited success. Various novel therapeutic approaches have recently emerged in lymphoma, demonstrating promising results. These include small molecules, novel monoclonal antibodies, antibody–drug conjugates (ADC), bispecific antibodies (BsAbs), and chimeric antigen receptor (CAR) T-cell therapy. This review explores recent advancements in therapeutic strategies for DLBCL and their potential impact on the initial management of DLBCL patients., This work was supported in part by the Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias [PI17/00943, PI22/01204].
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders

  • Serna, Angel
  • Iraola, Josu
  • Garcia-Herce, Cristina
  • Falcó Roget, Anna
  • Navarro Garces, Victor
  • Jiménez, Moraima
  • Bosch Schips, Marc
  • Albasanz Puig, Adaia
  • Ruiz- Camps, Isabel
  • Esperalba, Juliana
  • Cecilia del Carmen, Carpio Segura
  • Crespo, Marta
  • IACOBONI, GLORIA
  • Marin Niebla, Ana
  • Abrisqueta, Pau
  • Antón Pagarolas, Andrés
  • Andrés Vergés, Cristina
  • Bosch, Francesc
SARS-CoV-2 infection; Bispecific antibody; B-cell lymphoproliferative disorders, Infecció per SARS-CoV-2; Anticossos biespecífics; Trastorns limfoproliferatius de cèl·lules B, Infección por SARS-CoV-2; Anticuerpos biespecíficos; Trastornos linfoproliferativos de células B, Despite advances in vaccination and the use of antiviral treatments, patients with hematologic malignancies, including B-cell lymphoproliferative disorders, are particularly vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The recent introduction of bispecific antibodies (BsAbs) in the treatment algorithm of relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) has raised concerns regarding their impact on COVID-19 outcomes. This study aimed to evaluate the impact of SARS-CoV-2 infection on treatment outcomes in patients receiving BsAbs. We assessed the severity of COVID-19 and SARS-CoV-2 serostatus, with antibody titers measured before, during, and after BsAbs administration. A total of 109 patients with B-NHL treated with BsAbs from March 2020 to January 2023 were included. SARS-CoV-2 infection was observed in 56 patients (51%), with 36% experiencing prolonged viral shedding, causing therapy delays in 78% of patients and permanent discontinuations in 19%. Regarding COVID-19 severity, 36% of patients presented moderate, 20% severe, and 12% critical disease. Seven patients (13%) died owing to COVID-19 pneumonia. Similar to observations with anti-CD20 monoclonal antibodies, BsAbs were associated with negative antispike serostatus for at least 6 months after treatment completion. Importantly, this lack of seroconversion was linked with severe disease and increased mortality. These findings underscore important considerations for the management of patients receiving BsAbs., This work was supported by the Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias (PI22/01204).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemia

  • Medina-Gil, Daniel
  • Palomo Diaz, Laura
  • Lázaro, Gonzalo
  • Martín Mur, Beatriz
  • Hernández Pascual, Cristina
  • Castells, Oriol
  • Sánchez, Belén
  • Pagès Geli, Carlota
  • Pujadas, Gemma
  • Crespo, Marta
  • Navarro Garces, Victor
  • Muñoz-Torres, Pau Marc
  • Cabirta, Alba
  • Abrisqueta, Pau
  • Bosch, Francesc
Bruton tyrosine kinase covalent inhibition; Immune microenvironment; Chronic lymphocytic leukemia, Inhibición covalente de la tirosina quinasa de Bruton; Microambiente inmunitario; Leucemia linfocítica crónica, Inhibició covalent de la tirosina quinasa de Bruton; Microambient immunitari; Leucèmia limfocítica crònica, Continuous treatment with ibrutinib not only exerts tumor control but also enhances T-cell function in patients with chronic lymphocytic leukemia (CLL). We conducted longitudinal multi-omics analyses in samples from CLL patients receiving ibrutinib upfront to identify potential adaptive mechanisms to Bruton tyrosine kinase (BTK) inhibition during the first 12 months of continuous therapy. We found that ibrutinib induced a decrease in the expression of exhaustion markers and the proportion of regulatory T cells and T-follicular helper cells normalized to levels observed in healthy donors. Functionally, the expression of genes related to activation, proliferation, differentiation, and metabolism were downregulated in T cells; after in vitro stimulation, proliferation capacity was only slightly modified by ibrutinib treatment, while cytokine production was increased. In CLL cells, we observed a downregulation of immunosuppression, adhesion, and migration proteins. Adaptation at molecular level, characterized by an increase in cancer cell fraction of CLL cells with mutated driver genes, was observed in around half of the patients and was associated with retained migrative capacity towards CXCL12/CXCR4 axis. Interestingly, BTK C481S mutations were detected as early as after 6 months of treatment, particularly enriched in subsets of malignant cells retaining migrative capacity. These CLL cells with potential migrative capacity under ibrutinib also exhibited a distinct transcriptomic profile including upregulation of mTOR-AKT and MYC pathways. We identified the high expression of TMBIM6 as a potential novel independent poor prognostic factor. Of note, BIA, a TMBIM6 antagonist, induced CLL cell apoptosis and synergized with ibrutinib. In summary, our comprehensive multi-omics analysis of CLL patients undergoing ibrutinib therapy has unveiled early immunomodulatory effects on T cells and adaptative mechanisms in CLL cells. These findings can contribute to the identification of resistance mechanisms and the discovery of novel therapeutic targets., This work was supported by research funding from the Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias (PI21/01190, to MC) (PI20/01274 and PI24/00529 to FB), (PI22/01204 PA and Fundació la Marató de TV3 [201905-30-31] to FB). All Spanish funding was co-sponsored by the European Union FEDER program “Una manera de hacer Europa”. DM-G holds a contract from Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) (2022FI_B 00092).